Oscar Health FY2025 premium revenue rises 28% to USD 11.38 billion

Reuters
02/14
<a href="https://laohu8.com/S/OSCR">Oscar</a> Health FY2025 premium revenue rises 28% to USD 11.38 billion

Oscar Health Inc. reported its financial results for the full year ended December 31, 2025. Premium revenue increased by 28% to USD 11.36 billion, primarily driven by higher membership following above market growth during the 2025 Open Enrollment period. The company reported a net loss attributable to shareholders of USD 443.15 million for the period. Medical Loss Ratio $(MLR)$ stood at 87.4%, while the Selling, General, and Administrative (SG&A) expense ratio was 17.5%. As of December 31, 2025, Oscar Health Inc. had approximately 2.0 million effectuated members. During 2025, Oscar Health Inc. expanded its business by acquiring early-stage companies, including Lucie, Inc., a direct enrollment technology platform; IHC Specialty Benefits, Inc., an individual market brokerage; and Healthinsurance.org, LLC, a consumer education website. These acquisitions were aimed at supporting the company’s capabilities in Individual Coverage Health Reimbursement Arrangements (ICHRA) and diversifying its offerings. Oscar Health Inc. continues to focus on leveraging its technology platform and member experience, serving individuals, families, and employees through ACA plans and health technology solutions via its +Oscar platform.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oscar Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001568651-26-000011), on February 13, 2026, and is solely responsible for the information contained therein.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10